Galectin-1 induces hepatocellular carcinoma EMT and sorafenib resistance by activating FAK/PI3K/AKT signaling

Cell Death and Disease

Volumn 7, Issue 4, 2016, Pages

  Zhang, P F ^a   Li, K S ^b   Shen, Y H ^a   Gao, P T ^a   Dong, Z R ^a   Cai, J B ^a   Zhang, C ^a   Huang, X Y ^a   Tian, M X ^a   Hu, Z Q ^a   Gao, D M ^a   Fan, J ^a,c   Ke, A W ^a   Shi, G M ^a  

^a FUDAN UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; GALECTIN 1; SORAFENIB; VITRONECTIN RECEPTOR; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; CARBANILAMIDE DERIVATIVE; CHROMONE DERIVATIVE; FOCAL ADHESION KINASE 1; MORPHOLINE DERIVATIVE; NICOTINAMIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PTK2 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG RESPONSE; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE KNOCKDOWN; GENE OVEREXPRESSION; HCCLM3 CELL LINE; HEP 3B2.1-7 CELL LINE; HUH-7 CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MHCC97-H CELL LINE; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PI3K/AKT SIGNALING; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; RECURRENCE FREE SURVIVAL; TISSUE MICROARRAY; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR XENOGRAFT; UPREGULATION; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; LIVER NEOPLASMS; METABOLISM; MORTALITY; NUDE MOUSE; PATHOLOGY; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SURVIVAL RATE; TUMOR CELL LINE; TUMOR INVASION;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMONES; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; FOCAL ADHESION KINASE 1; GALECTIN 1; HUMANS; INTEGRIN ALPHAVBETA3; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED C57BL; MICE, NUDE; MORPHOLINES; NEOPLASM INVASIVENESS; NIACINAMIDE; PHENYLUREA COMPOUNDS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SURVIVAL RATE;

EID: 84991749451     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2015.324     Document Type: Article

References (33)

1. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907–1917.
2. Carr BI. Hepatocellular carcinoma: current management and future trends. Gastroenterology 2004; 127: S218–S224.
3. Zhu AX. Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be? Oncologist 2006; 11: 790–800.
4. Hernandez-Gea V, Toffanin S, Friedman SL, Llovet JM. Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology 2013; 144: 512–527.
5. Llovet JM, Hernandez-Gea V. Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design. Clin Cancer Res 2014; 20: 2072–2079.
6. Ke AW, Shi GM, Zhou J, Huang XY, Shi YH, Ding ZB et al. CD151 amplifies signaling by integrin alpha6beta1 to PI3K and induces the epithelial-mesenchymal transition in HCC cells. Gastroenterology 2011; 140: 1629–1641.
7. Ding W, You H, Dang H, LeBlanc F, Galicia V, Lu SC et al. Epithelial-to-mesenchymal transition of murine liver tumor cells promotes invasion. Hepatology 2010; 52: 945–953.
8. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378–390.
9. Copur MS. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 2498.
10. Dufour JF. The evasive promise of antiangiogenic therapy. J Hepatol 2009; 51: 970–972.
11. Ito K, Stannard K, Gabutero E, Clark AM, Neo SY, Onturk S et al. Galectin-1 as a potent target for cancer therapy: role in the tumor microenvironment. Cancer Metastasis Rev 2012; 31: 763–778.
12. Zhang P, Zhang P, Shi B, Zhou M, Jiang H, Zhang H et al. Galectin-1 overexpression promotes progression and chemoresistance to cisplatin in epithelial ovarian cancer. Cell Death Dis 2014; 5: e991.
13. White NM, Masui O, Newsted D, Scorilas A, Romaschin AD, Bjarnason GA et al. Galectin-1 has potential prognostic significance and is implicated in clear cell renal cell carcinoma progression through the HIF/mTOR signaling axis. Br J cancer 2014; 110: 1250–1259.
14. Huang XY, Ke AW, Shi GM, Zhang X, Zhang C, Shi YH et al. AlphaB-crystallin complexes with 14-3-3zeta to induce epithelial-mesenchymal transition and resistance to sorafenib in hepatocellular carcinoma. Hepatology 2013; 57: 2235–2247.
15. Zhai B, Sun XY. Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma. World J Hepatol 2013; 5: 345–352.
16. Guo W, Giancotti FG. Integrin signalling during tumour progression. Nat Rev Mol Cell Biol 2004; 5: 816–826.
17. Berghoff AS, Kovanda AK, Melchardt T, Bartsch R, Hainfellner JA, Sipos B et al. Alphavbeta3, alphavbeta5 and alphavbeta6 integrins in brain metastases of lung cancer. Clin Exp Metastasis 2014; 31: 841–851.
18. Desgrosellier JS, Lesperance J, Seguin L, Gozo M, Kato S, Franovic A et al. Integrin alphavbeta3 drives slug activation and stemness in the pregnant and neoplastic mammary gland. Dev Cell 2014; 30: 295–308.
19. Kannan N, Nguyen LV, Eaves CJ. Integrin beta3 links therapy resistance and cancer stem cell properties. Nat Cell Biol 2014; 16: 397–399.
20. Seguin L, Kato S, Franovic A, Camargo MF, Lesperance J, Elliott KC et al. An integrin beta (3)-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition. Nat Cell Biol 2014; 16: 457–468.
21. Martinez-Bosch N, Fernandez-Barrena MG, Moreno M, Ortiz-Zapater E, Munne-Collado J, Iglesias M et al. Galectin-1 drives pancreatic carcinogenesis through stroma remodeling and Hedgehog signaling activation. Cancer Res 2014; 74: 3512–3524.
22. Hsu YL, Wu CY, Hung JY, Lin YS, Huang MS, Kuo PL. Galectin-1 promotes lung cancer tumor metastasis by potentiating integrin alpha6beta4 and Notch1/Jagged2 signaling pathway. Carcinogenesis 2013; 34: 1370–1381.
23. Xia L, Huang W, Tian D, Zhu H, Qi X, Chen Z et al. Overexpression of forkhead box C1 promotes tumor metastasis and indicates poor prognosis in hepatocellular carcinoma. Hepatology 2013; 57: 610–624.
24. Astorgues-Xerri L, Riveiro ME, Tijeras-Raballand A, Serova M, Neuzillet C, Albert S et al. Unraveling galectin-1 as a novel therapeutic target for cancer. Cancer Treat Rev 2014; 40: 307–319.
25. Neuzillet C, Tijeras-Raballand A, de Mestier L, Cros J, Faivre S, Raymond E. MEK in cancer and cancer therapy. Pharmacol Ther 2014; 141: 160–171.
26. Huang CS, Tang SJ, Chung LY, Yu CP, Ho JY, Cha TL et al. Galectin-1 upregulates CXCR4 to promote tumor progression and poor outcome in kidney cancer. J Am Soc Nephrol 2014; 25: 1486–1495.
27. Lv B, Yang X, Lv S, Wang L, Fan K, Shi R et al. CXCR4 signaling induced epithelial-mesenchymal transition by PI3K/AKT and ERK pathways in glioblastoma. Mol Neurobiol 2014; 52: 1263–1268.
28. Tam WL, Weinberg RA. The epigenetics of epithelial-mesenchymal plasticity in cancer. Nat Med 2013; 19: 1438–1449.
29. Shang Y, Cai X, Fan D. Roles of epithelial-mesenchymal transition in cancer drug resistance. Curr Cancer Drug Targets 2013; 13: 915–929.
30. Wang Z, Li Y, Ahmad A, Azmi AS, Kong D, Banerjee S et al. Targeting miRNAs involved in cancer stem cell and EMT regulation: an emerging concept in overcoming drug resistance. Drug Resist Updat 2010; 13: 109–118.
31. van Malenstein H, Dekervel J, Verslype C, Van Cutsem E, Windmolders P, Nevens F et al. Long-term exposure to sorafenib of liver cancer cells induces resistance with epithelial-to-mesenchymal transition, increased invasion and risk of rebound growth. Cancer Lett 2013; 329: 74–83.
32. Tao ZH, Wan JL, Zeng LY, Xie L, Sun HC, Qin LX et al. miR-612 suppresses the invasive-metastatic cascade in hepatocellular carcinoma. J Exp Med 2013; 210: 789–803.
33. Zhang P, Shi B, Gao H, Jiang H, Kong J, Yan J et al. An EpCAM/CD3 bispecific antibody efficiently eliminates hepatocellular carcinoma cells with limited galectin-1 expression. Cancer Immunol Immunother 2014; 63: 121–132.